Nanotechnology is a ‘disruptive technology’, which can lead to a generation of new diagnostic and therapeutic products, resulting
in dramatically improved cancer outcomes. The National Cancer Institute (NCI) of National Institutes of Health explores innovative
approaches to multidisciplinary research allowing for a convergence of molecular biology, oncology, physics, chemistry, and
engineering and leading to the development of clinically worthy technological approaches. These initiatives include programmatic
efforts to enable nanotechnology as a driver of advances in clinical oncology and cancer research, known collectively as the
NCI Alliance for Nanotechnology in Cancer (ANC). Over the last 5 years, ANC has demonstrated that multidisciplinary approach
catalyzes scientific developments and advances clinical translation in cancer nanotechnology. The research conducted by ANC
members has improved diagnostic assays and imaging agents, leading to the development of point‐of‐care diagnostics, identification
and validation of numerous biomarkers for novel diagnostic assays, and the development of multifunctional agents for imaging
and therapy. Numerous nanotechnology‐based technologies developed by ANC researchers are entering clinical trials. NCI has
re‐issued ANC program for next 5 years signaling that it continues to have high expectations for cancer nanotechnology's impact
on clinical practice. The goals of the next phase will be to broaden access to cancer nanotechnology research through greater
clinical translation and outreach to the patient and clinical communities and to support development of entirely new models
of cancer care. WIREs Nanomed Nanobiotechnol 2010 2 450–460
NCI Alliance for Nanotechnology in Cancer awarded institutions (2005–2010): Centers of Cancer Nanotechnology Excellence (in red) and Cancer Nanotechnology Platform Partnerships (in blue).
Research Articles in Cancer Nanotechnology from 2002 to 2009. The information was retrieved from MEDLINE/PubMED indexed articles using the U.S. National Library of Medicine's Medical Subject Headings (MESH) terminology related to ‘cancer’ and ‘nanotechnology’.
works at the interface of biotechnology and materials science. His lab is researching many topics, such as investigating the mechanism of release from polymeric delivery systems with concomitant microstructural analysis and mathematical modeling; studying applications of these systems including the development of effective long-term delivery systems for insulin, anti-cancer drugs, growth factors, gene therapy agents and vaccines; developing controlled release systems that can be magnetically, ultrasonically, or enzymatically triggered to increase release rates; synthesizing new biodegradable polymeric delivery systems which will ultimately be absorbed by the body; creating new approaches for delivering drugs such as proteins and genes across complex barriers such as the blood-brain barrier, the intestine, the lung and the skin; stem cell research including controlling growth and differentiation; and creating new biomaterials with shape memory or surface switching properties.